Assorted News from Last Week: The Coalition Against Childhood Cancer is pleased to announce the 2022 Annual Summit hosted by Children’s Hospital of Philadelphia and presented by Day One Biopharmaceuticals. This annual event reflects the CAC2 values and mission by providing top-notch educational programming, designing multiple opportunities for members to connect and engage, and showcasing the ongoing work of our members who are working for a future without childhood cancers. The Alliance for Childhood Cancer sends its thanks for a fantastic Action Day on April 28! Nearly 300 advocates from 39 states and Washington, DC participated and attended almost 200 […]
Read moreDuring last week’s Childhood Cancer Action Day, legislation to reauthorize the Childhood Cancer STAR Act was introduced in both chambers of Congress! The original STAR Act was signed into law in 2018 after unprecedented support from our community. It authorized five years of funding at $30 million annually from 2019-2023. Also, thanks to the community’s efforts the STAR Act has subsequently received those expected appropriations of $30 million each year. The STAR Act represents important bipartisan legislation designed to advance pediatric cancer research and child-focused cancer treatments, while also improving childhood cancer surveillance and providing enhanced resources for survivors. On April […]
Read moreThe Alliance for Childhood Cancer sends its thanks for a fantastic Action Day on April 28! Nearly 300 advocates from 39 states and Washington, DC participated and attended almost 200 meetings sharing their stories and asking for congressional support for important legislation and funding for childhood cancer. CAC2 members, Alliance members, and many others across the country had their voices heard. This year’s top line asks: We urge Congress to provide significant funding increases for the National Institutes of Health (NIH) and National Cancer Institute (NCI) and to fully support childhood cancer programs, including providing $30 million to fully fund […]
Read moreAssorted News from Last Week: The Coalition Against Childhood Cancer is pleased to announce the 2022 Annual Summit hosted by Children’s Hospital of Philadelphia and presented by Day One Biopharmaceuticals. This annual event reflects the CAC2 values and mission by providing top-notch educational programming, designing multiple opportunities for members to connect and engage, and showcasing the ongoing work of our members who are working for a future without childhood cancers. The Alliance for Childhood Cancer will hold its 11th Annual Childhood Cancer Action Days on Thursday, April 28. This virtual event brings our community together to advocate for important childhood […]
Read moreAssorted News from Last Week: The Coalition Against Childhood Cancer is pleased to announce the 2022 Annual Summit hosted by Children’s Hospital of Philadelphia and presented by Day One Biopharmaceuticals. This annual event reflects the CAC2 values and mission by providing top-notch educational programming, designing multiple opportunities for members to connect and engage, and showcasing the ongoing work of our members who are working for a future without childhood cancers. Why is investing in drugs to treat rare diseases an attractive investment for drug companies? A compendium on CAR-T Cell Therapy from the National Cancer Institute. Methionine restriction may improve […]
Read moreAssorted News from Last Week: The Coalition Against Childhood Cancer is pleased to announce the 2022 Annual Summit hosted by Children’s Hospital of Philadelphia and presented by Day One Biopharmaceuticals. This annual event reflects the CAC2 values and mission by providing top-notch educational programming, designing multiple opportunities for members to connect and engage, and showcasing the ongoing work of our members who are working for a future without childhood cancers. The Research to Accelerate Cures and Equity (RACE) Act led to an increase in required pediatric studies for recently approved cancer therapies within the first year of the act’s implementation, […]
Read moreAssorted News from Last Week: Cancer survivors have increasingly advocated for research into the long-term effects of their treatment. Read more about that perspective from post doctoral research scientist and long-term childhood leukemia survivor, Victoria J. Forster. Treatment for glioma has long relied on MRI imaging to track tumor markers and treatment response. But new findings suggest a new method could provide additional data about tumor markers before changes appear on an MRI, indicating possible strategies to help clinicians address this aggressive form of cancer. Scientists have identified variants in two genes that are associated with accelerated aging in childhood […]
Read moreThe National Cancer Institute’s new Molecular Characterization Initiative (MCI) fosters data sharing in childhood cancer research. The program currently offers comprehensive molecular characterization of tumors to children, adolescents, and young adults (AYAs) with newly diagnosed central nervous system tumors receiving care at hospitals affiliated with the Children’s Oncology Group. The DNA and RNA in participants’ tumors are analyzed through this voluntary, free program. Participants’ tumor and blood samples are analyzed in an accredited lab, with results shared with families and doctors within 21 days. This detailed information about the cancer can be used to make a more precise diagnosis, […]
Read moreAssorted News from Last Week:
Read more